Synergistic effect of celecoxib in tumor necrosis factor‑related apoptosis‑inducing ligand treatment in osteosarcoma cells

Liu,Gong; Yu,Ming-Yang; Huang,Xu; Zhu,Dong; Cheng,Shihuan; Ma,Renshi; Gu,Guishan

doi:10.3892/mmr.2014.2409

Synergistic effect of celecoxib in tumor necrosis factor‑related apoptosis‑inducing ligand treatment in osteosarcoma cells

Authors:
- Gong Liu
- Ming-Yang Yu
- Xu Huang
- Dong Zhu
- Shihuan Cheng
- Renshi Ma
- Guishan Gu
View Affiliations

Affiliations: Department of Orthopaedics, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: July 22, 2014 https://doi.org/10.3892/mmr.2014.2409
Pages: 2198-2202

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor necrosis factor-related apoptosis‑inducing ligand (TRAIL) is under clinical development as a cancer therapeutic as it has been shown to induce apoptosis in numerous types of cancer cells without significant toxicity towards normal cells. However, the majority of osteosarcoma (OS) tumors are resistant to TRAIL. Thus, the development of cancer therapeutics that overcome TRAIL resistance is required. In the present study, celecoxib (CXB), a non-steroidal anti‑inflammatory drug, was administered in combination with TRAIL to induce cell apoptosis and the doses of the two drugs were simultaneously reduced. The effects of this combination treatment were examined in MG-63 human OS cancer cell lines in culture. Assays of proliferation, apoptosis and tumor growth were performed, along with analysis of the proteins involved. The results revealed that CXB sensitized TRAIL-resistant MG-63 OS cells to TRAIL‑induced apoptosis through downregulation of cellular B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein, caspase-8 and caspase-3. Furthermore, combination treatment reduced tumor growth in a nude rat model. In conclusion, the experimental results provided evidence that the combined administration of CXB and TRAIL is potentially a novel treatment method of OS tumors.

View Figures

View References

1	Caronia D, Patiño-Garcia A, Peréz-Martínez A, et al: Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PLoS One. 6:e260912011. View Article : Google Scholar : PubMed/NCBI
2	Bacci G, Balladelli A, Palmerini E, et al: Neoadjuvant chemotherapy for osteosarcoma of the extremities in preadolescent patients: the Rizzoli Institute experience. J Pediatr Hematol Oncol. 30:908–912. 2008. View Article : Google Scholar
3	Ta HT, Dass CR, Choong PF and Dunstan DE: Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
4	Gorlick R, Anderson P, Andrulis I, et al: Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res. 9:5442–5453. 2003.PubMed/NCBI
5	Mérino D, Lalaoui N, Morizot A, Solary E and Micheau O: TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets. 11:1299–1314. 2007.
6	Johnstone RW, Frew AJ and Smyth MJ: The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer. 8:782–798. 2008. View Article : Google Scholar : PubMed/NCBI
7	Almasan A and Ashkenazi A: Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14:337–348. 2003. View Article : Google Scholar : PubMed/NCBI
8	Ashkenazi A, Holland P and Eckhardt SG: Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol. 26:3621–3630. 2008. View Article : Google Scholar
9	Walczak H, Miller RE, Ariail K, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 5:157–163. 1999. View Article : Google Scholar : PubMed/NCBI
10	Ganten TM, Haas TL, Sykora J, et al: Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ. 11(Suppl 1): S86–S96. 2004. View Article : Google Scholar
11	Gómez-Benito M, Martinez-Lorenzo MJ, Anel A, Marzo I and Naval J: Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Exp Cell Res. 313:2378–2388. 2007.PubMed/NCBI
12	Schuchmann M, Schulze-Bergkamen H, Fleischer B, et al: Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95-and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep. 15:227–230. 2006.
13	He SQ, Rehman H, Gong MG, et al: Inhibiting survivin expression enhances TRAIL-induced tumoricidal activity in human hepatocellular carcinoma via cell cycle arrest. Cancer Biol Ther. 6:1247–1257. 2007.
14	Han J, Goldstein LA, Gastman BR and Rabinowich H: Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem. 281:10153–10163. 2006. View Article : Google Scholar : PubMed/NCBI
15	Bortul R, Tazzari PL, Cappellini A, et al: Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation. Leukemia. 17:379–389. 2003. View Article : Google Scholar
16	Bosch FX, Ribes J and Borras J: Epidemiology of primary liver cancer. Semin Liver Dis. 19:271–285. 1999. View Article : Google Scholar : PubMed/NCBI
17	Winfield LL and Payton-Stewart F: Celecoxib and Bcl-2: emerging possibilities for anticancer drug design. Future Med Chem. 4:361–383. 2012. View Article : Google Scholar : PubMed/NCBI
18	Wei D, Wang L, He Y, et al: Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res. 64:2030–2038. 2004. View Article : Google Scholar
19	Jeon YW and Suh YJ: Synergistic apoptotic effect of celecoxib and luteolin on breast cancer cells. Oncol Rep. 29:819–825. 2013.PubMed/NCBI
20	Mikuła-Pietrasik J, Kuczmarska A, Kucińska M, et al: Resveratrol and its synthetic derivatives exert opposite effects on mesothelial cell-dependent angiogenesis via modulating secretion of VEGF and IL-8/CXCL8. Angiogenesis. 15:361–376. 2012.PubMed/NCBI
21	Yoshida S, Amano H, Hayashi I, et al: COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. Lab Invest. 83:1385–1394. 2003. View Article : Google Scholar : PubMed/NCBI
22	Zhang X, Zou Y, Mao Y, et al: Preclinical toxicity of DATR, a recombinant soluble human TRAIL mutant, in rats and cynomolgus monkeys. Regul Toxicol Pharmacol. 61:230–235. 2011. View Article : Google Scholar : PubMed/NCBI
23	Ashkenazi A: Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2:420–430. 2002. View Article : Google Scholar : PubMed/NCBI
24	Koschny R, Walczak H and Ganten TM: The promise of TRAIL - potential and risks of a novel anticancer therapy. J Mol Med (Berl). 85:923–935. 2007. View Article : Google Scholar : PubMed/NCBI
25	Cuello M, Ettenberg SA, Nau MM and Lipkowitz S: Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol. 81:380–390. 2001. View Article : Google Scholar : PubMed/NCBI
26	Nagane M, Pan G, Weddle JJ, et al: Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res. 60:847–853. 2000.
27	Gaiser T, Becker MR, Habel A, et al: TRAIL-mediated apoptosis in malignant glioma cells is augmented by celecoxib through proteasomal degradation of survivin. Neurosci Lett. 442:109–113. 2008. View Article : Google Scholar : PubMed/NCBI
28	Lu G, Liu Y, Ji B, et al: Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells. Cancer Invest. 28:629–634. 2010. View Article : Google Scholar : PubMed/NCBI
29	Ullah MF: Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac J Cancer Prev. 9:1–6. 2008.PubMed/NCBI
30	Irie T, Tsujii M, Tsuji S, et al: Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma. Int J Cancer. 121:878–883. 2007. View Article : Google Scholar : PubMed/NCBI